These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 27660272

  • 1. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
    Reis SD, Pinho BR, Oliveira JMA.
    Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
    [Abstract] [Full Text] [Related]

  • 2. Targeting the proteostasis network in Huntington's disease.
    Soares TR, Reis SD, Pinho BR, Duchen MR, Oliveira JMA.
    Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498
    [Abstract] [Full Text] [Related]

  • 3. [Molecular biology of polyglutamine diseases].
    Owecki M, Kozubski W.
    Postepy Hig Med Dosw; 2002 Jan; 56(6):779-88. PubMed ID: 12661407
    [Abstract] [Full Text] [Related]

  • 4. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF, Jiang H, Tang JG, Tang BS.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [Abstract] [Full Text] [Related]

  • 5. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A.
    J Mol Neurosci; 2004 Aug; 23(1-2):69-96. PubMed ID: 15126694
    [Abstract] [Full Text] [Related]

  • 6. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN, Eremeev AV, Pozmogova GE, Lagarkova MA.
    Mol Biol (Mosk); 2019 Aug; 53(6):954-967. PubMed ID: 31876275
    [Abstract] [Full Text] [Related]

  • 7. Salvage NAD+ biosynthetic pathway enzymes moonlight as molecular chaperones to protect against proteotoxicity.
    Pinkerton M, Ruetenik A, Bazylianska V, Nyvltova E, Barrientos A.
    Hum Mol Genet; 2021 May 17; 30(8):672-686. PubMed ID: 33749726
    [Abstract] [Full Text] [Related]

  • 8. Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.
    Davis AK, Pratt WB, Lieberman AP, Osawa Y.
    Cell Mol Life Sci; 2020 Mar 17; 77(6):977-996. PubMed ID: 31552448
    [Abstract] [Full Text] [Related]

  • 9. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A, Hoarau-Véchot J, Ladjimi M.
    Int J Biol Macromol; 2013 Sep 17; 60():196-205. PubMed ID: 23748003
    [Abstract] [Full Text] [Related]

  • 10. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA.
    Neuron; 2002 Aug 29; 35(5):819-22. PubMed ID: 12372277
    [Abstract] [Full Text] [Related]

  • 11. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M, Watanabe H, Yamamoto M, Sobue G.
    Expert Rev Neurother; 2014 Oct 29; 14(10):1215-28. PubMed ID: 25190502
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila.
    Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM.
    Hum Mol Genet; 2000 Nov 22; 9(19):2811-20. PubMed ID: 11092757
    [Abstract] [Full Text] [Related]

  • 13. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy.
    Bailey CK, Andriola IF, Kampinga HH, Merry DE.
    Hum Mol Genet; 2002 Mar 01; 11(5):515-23. PubMed ID: 11875046
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Polyglutamine diseases.
    Bunting EL, Hamilton J, Tabrizi SJ.
    Curr Opin Neurobiol; 2022 Feb 01; 72():39-47. PubMed ID: 34488036
    [Abstract] [Full Text] [Related]

  • 18. Hsp70 molecular chaperones and Parkinson's disease.
    Witt SN.
    Biopolymers; 2010 Mar 01; 93(3):218-28. PubMed ID: 19768775
    [Abstract] [Full Text] [Related]

  • 19. Proteostasis of Huntingtin in Health and Disease.
    Koyuncu S, Fatima A, Gutierrez-Garcia R, Vilchez D.
    Int J Mol Sci; 2017 Jul 19; 18(7):. PubMed ID: 28753941
    [Abstract] [Full Text] [Related]

  • 20. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y, Fujikake N, Popiel HA, Wada K.
    Curr Pharm Biotechnol; 2010 Feb 19; 11(2):188-97. PubMed ID: 20166962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.